BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kanwal F, Farid M, Martin P, Chen G, Gralnek IM, Dulai GS, Spiegel BMR. Treatment Alternatives for Hepatitis B Cirrhosis: A Cost-Effectiveness Analysis. Am J Gastroenterol 2006;101:2076-89. [DOI: 10.1111/j.1572-0241.2006.00769.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Idris BI, Brosa M, Richardus JH, Esteban R, Schalm SW, Buti M. Estimating the future health burden of chronic hepatitis B and the impact of therapy in Spain: . European Journal of Gastroenterology & Hepatology 2008;20:320-6. [DOI: 10.1097/meg.0b013e3282f340c8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
2 Nayeri UA, Werner EF, Han CS, Pettker CM, Funai EF, Thung SF. Antenatal lamivudine to reduce perinatal hepatitis B transmission: a cost-effectiveness analysis. American Journal of Obstetrics and Gynecology 2012;207:231.e1-7. [DOI: 10.1016/j.ajog.2012.06.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
3 Zhang H, Huo M, Chao J, Liu P. Application of Bayesian Approach to Cost-Effectiveness Analysis of Antiviral Treatments in Chronic Hepatitis B. PLoS One 2016;11:e0161936. [PMID: 27574976 DOI: 10.1371/journal.pone.0161936] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
4 Ruggeri M, Coretti S, Gasbarrini A, Cicchetti A. Economic Assessment of an Anti-HCV Screening Program in Italy. Value in Health 2013;16:965-72. [DOI: 10.1016/j.jval.2013.07.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
5 Huisman EL, van Eerd MC, Ouwens JN, de Peuter MA. Cost-effectiveness and budget impact study of solvent/detergent (SD) treated plasma (octaplasLG®) versus fresh-frozen plasma (FFP) in any patient receiving transfusion in Canada. Transfus Apher Sci 2014;51:25-34. [PMID: 23707561 DOI: 10.1016/j.transci.2013.04.045] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
6 Babigumira JB, Lubinga SJ, Castro E, Custer B. Cost-utility and budget impact of methylene blue-treated plasma compared to quarantine plasma. Blood Transfus 2018;16:154-62. [PMID: 27893348 DOI: 10.2450/2016.0130-16] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Lee H, Kim BK, Jang S, Ahn SH. Cost-Effectiveness Analysis of Antiviral Therapy for Untreated Minimally Active Chronic Hepatitis B to Prevent Liver Disease Progression. Clin Transl Gastroenterol 2021;12:e00299. [PMID: 33600103 DOI: 10.14309/ctg.0000000000000299] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Wong WW, Woo G, Heathcote EJ, Krahn M. Disease burden of chronic hepatitis B among immigrants in Canada. Can J Gastroenterol 2013;27:137-47. [PMID: 23516678 DOI: 10.1155/2013/924640] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
9 You JH, Chan FW. Pharmacoeconomics of entecavir treatment for chronic hepatitis B. Expert Opinion on Pharmacotherapy 2008;9:2673-81. [DOI: 10.1517/14656566.9.15.2673] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
10 Ruggeri M, Cicchetti A, Gasbarrini A. The cost-effectiveness of alternative strategies against HBV in Italy. Health Policy 2011;102:72-80. [DOI: 10.1016/j.healthpol.2010.09.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
11 Ashtari S, Vahedi M, Pourhoseingholi MA, Karkhane M, Kimiia Z, Pourhoseingholi A, Safaee A, Moghimi-Dehkordi B, Zali MR, Alavian SM. Direct medical care costs associated with patients diagnosed with chronic HCV. Hepat Mon. 2013;13:e8415. [PMID: 23930132 DOI: 10.5812/hepatmon.8415] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
12 Fan L, Owusu-Edusei K Jr, Schillie SF, Murphy TV. Cost-effectiveness of active-passive prophylaxis and antiviral prophylaxis during pregnancy to prevent perinatal hepatitis B virus infection. Hepatology. 2016;63:1471-1480. [PMID: 26509655 DOI: 10.1002/hep.28310] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 4.9] [Reference Citation Analysis]
13 Tian N, Liu Z, Yang M, Li Z, Zhang G, Han Q, Li N, Zhu Q, Lv Y, Wang Y, Xing F. Effect of antiviral therapy on the survival and incidence of major complications in HBV-associated cirrhotic patients after splenectomy for hypersplenism and portal hypertension. Virol J 2012;9:273. [PMID: 23158807 DOI: 10.1186/1743-422X-9-273] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
14 Post SE, Sodhi NK, Peng CH, Wan K, Pollack HJ. A simulation shows that early treatment of chronic hepatitis B infection can cut deaths and be cost-effective. Health Aff (Millwood) 2011;30:340-8. [PMID: 21289356 DOI: 10.1377/hlthaff.2008.0905] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
15 Paik CN, Kim SW, Lee IS, Park JM, Cho YK, Choi MG, Chung IS. The therapeutic effect of cyanoacrylate on gastric variceal bleeding and factors related to clinical outcome. J Clin Gastroenterol. 2008;42:916-922. [PMID: 18645533 DOI: 10.1097/MCG.0b013e31811edcd1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
16 Dan YY, Aung MO, Lim SG. The economics of treating chronic hepatitis B in Asia. Hepatol Int 2008;2:284-95. [PMID: 19669256 DOI: 10.1007/s12072-008-9049-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
17 Jazwa A, Coleman MS, Gazmararian J, Wingate LT, Maskery B, Mitchell T, Weinberg M. Cost-benefit comparison of two proposed overseas programs for reducing chronic Hepatitis B infection among refugees: is screening essential? Vaccine 2015;33:1393-9. [PMID: 25595868 DOI: 10.1016/j.vaccine.2015.01.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
18 Altinbas A, Baser E, Burkan A, Ertugay E, Kariburyo MF, Baser O. Retrospective analysis of total direct medical costs associated with hepatitis B patients with oral antiviral versus pegylated interferon therapy in Turkey. J Viral Hepat 2014;21:794-801. [DOI: 10.1111/jvh.12206] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
19 Veldhuijzen IK, Toy M, Hahné SJ, De Wit GA, Schalm SW, de Man RA, Richardus JH. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective. Gastroenterology. 2010;138:522-530. [PMID: 19879275 DOI: 10.1053/j.gastro.2009.10.039] [Cited by in Crossref: 82] [Cited by in F6Publishing: 83] [Article Influence: 6.3] [Reference Citation Analysis]
20 Xiridou M, Visser M, Urbanus A, Matser A, van Benthem B, Veldhuijzen I. Ending risk-group HBV vaccination for MSM after the introduction of universal infant HBV vaccination: A mathematical modelling study. Vaccine 2021;39:2867-75. [PMID: 33896665 DOI: 10.1016/j.vaccine.2021.04.008] [Reference Citation Analysis]
21 Toy M, Onder FO, Idilman R, Kabacam G, Richardus JH, Bozdayi M, Akdogan M, Kuloglu Z, Kansu A, Schalm S, Yurdaydin C. The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country. Eur J Health Econ 2012;13:663-76. [PMID: 22815098 DOI: 10.1007/s10198-012-0413-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
22 Chinnaratha MA, Kaambwa B, Woodman RJ, Fraser RJ, Wigg AJ. Assessing the clinical and economic impact of increasing treatment uptake in chronic hepatitis B infection using a Markov model. J Gastroenterol Hepatol 2017;32:1370-7. [PMID: 28002881 DOI: 10.1111/jgh.13679] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
23 Buti M, Oyagüez I, Lozano V, Casado MA. Cost effectiveness of first-line oral antiviral therapies for chronic hepatitis B: a systematic review. Pharmacoeconomics. 2013;31:63-75. [PMID: 23329593 DOI: 10.1007/s40273-012-0009-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
24 Kim JH, Yim HJ, Jung ES, Jung YK, Kim JH, Seo YS, Yeon JE, Lee HS, Um SH, Byun KS. Virologic and biochemical responses to clevudine in patients with chronic HBV infection-associated cirrhosis: data at week 48. J Viral Hepat. 2011;18:287-293. [PMID: 20367793 DOI: 10.1111/j.1365-2893.2010.01304.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
25 Wong WW, Hicks LK, Tu HA, Pritchard KI, Krahn MD, Feld JJ, Chan KK. Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis. Breast Cancer Res Treat 2015;151:639-52. [PMID: 25962692 DOI: 10.1007/s10549-015-3382-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
26 Wei L, Hu S, Hou J, Liu G, Ren H, Duan Z, Xie Q, Fang X, Jia J. A Novel Estimation of the Impact of Treatment with Entecavir on Long-Term Mortality, Morbidity, and Health Care Costs of Chronic Hepatitis B in China. Value Health Reg Issues 2013;2:48-56. [PMID: 29702852 DOI: 10.1016/j.vhri.2013.02.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
27 Enriquez AD, Campbell MS, Reddy KR. Cost-effectiveness of suppressing hepatitis B virus DNA in immune tolerant patients to prevent hepatocellular carcinoma and cirrhosis: TREATMENT OF IMMUNE TOLERANT HBV. Alimentary Pharmacology & Therapeutics 2007;26:383-91. [DOI: 10.1111/j.1365-2036.2007.03382.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
28 Rajendra A, Wong JB. Economics of chronic hepatitis B and hepatitis C. Journal of Hepatology 2007;47:608-17. [DOI: 10.1016/j.jhep.2007.07.016] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
29 Tian F, Houle SKD, Alsabbagh MW, Wong WWL. Cost-Effectiveness of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B in Canada. Pharmacoeconomics 2020;38:181-92. [PMID: 31691902 DOI: 10.1007/s40273-019-00852-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
30 Tian F, Feld JJ, Feng Z, Sander B, Wong WWL. Feasibility of hepatitis B elimination in high-income countries with ongoing immigration. J Hepatol 2022:S0168-8278(22)00249-5. [PMID: 35483535 DOI: 10.1016/j.jhep.2022.04.014] [Reference Citation Analysis]
31 Tsai N, Jeffers L, Cragin L, Sorensen S, Su W, Rosenblatt L, Tang H, Hebden T, Juday T. Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective. Clinicoecon Outcomes Res. 2012;4:227-235. [PMID: 22977309 DOI: 10.2147/ceor.s31784] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
32 Pourhoseingholi MA, Ashtari S, Alavian SM. Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin; How Much Shall Pay for Iranian Patients? Hepat Mon 2014;14:e25540. [PMID: 25598793 DOI: 10.5812/hepatmon.25540] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
33 Gish R, Jia JD, Locarnini S, Zoulim F. Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis. 2012;12:341-353. [PMID: 22326017 DOI: 10.1016/s1473-3099(11)70314-0] [Cited by in Crossref: 98] [Cited by in F6Publishing: 39] [Article Influence: 9.8] [Reference Citation Analysis]
34 Coffin CS, Terrault NA. Management of hepatitis B in liver transplant recipients. J Viral Hepat. 2007;14 Suppl 1:37-44. [PMID: 17958641 DOI: 10.1111/j.1365-2893.2007.00916.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
35 Arnold RJG. Cost-effectiveness analysis: should it be required for drug registration and beyond? Drug Discovery Today 2007;12:960-5. [DOI: 10.1016/j.drudis.2007.09.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
36 Mohammadzadeh M, Fattahi B, Ghari T. The Estimation of Economic Burden of Hepatitis B Virus Infection in Iran. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.40541] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
37 Subramaniam K, Flexman J, Tarquinio L, Thambiran A, Hopkins S, Cheng W. Hepatitis B status in migrants and refugees: increasing health burden in Western Australia. Intern Med J 2012;42:880-6. [PMID: 22212294 DOI: 10.1111/j.1445-5994.2011.02711.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
38 Goyal A, Murray JM. Cost-Effectiveness of Peg-Interferon, Interferon and Oral Nucleoside Analogues in the Treatment of Chronic Hepatitis B and D Infections in China. Clin Drug Investig 2016;36:637-48. [DOI: 10.1007/s40261-016-0409-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
39 Beckebaum S, Sotiropoulos GC, Gerken G, Cicinnati VR. Hepatitis B and liver transplantation: 2008 update. Rev Med Virol 2009;19:7-29. [DOI: 10.1002/rmv.595] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
40 Han K, Kim DY. Chronic HBV infection with persistently normal ALT b. not to treat. Hepatol Int 2008;2:185-9. [DOI: 10.1007/s12072-008-9068-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
41 Spackman DE, Veenstra DL. A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B. Pharmacoeconomics 2008;26:937-49. [PMID: 18850763 DOI: 10.2165/00019053-200826110-00006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
42 Dai Z, Wong IOL, Xie C, Xu W, Xiang Y, Peng L, Lau EHY. Cost-effectiveness analysis of first-line treatment for chronic hepatitis B in China. Clin Microbiol Infect 2021:S1198-743X(21)00344-X. [PMID: 34197929 DOI: 10.1016/j.cmi.2021.06.024] [Reference Citation Analysis]
43 Fan L, Owusu-Edusei K Jr, Schillie SF, Murphy TV. Cost-effectiveness of testing hepatitis B-positive pregnant women for hepatitis B e antigen or viral load. Obstet Gynecol. 2014;123:929-937. [PMID: 24785842 DOI: 10.1097/aog.0000000000000124] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
44 Vallet-Pichard A, Pol S. [Management of hepatitis B virus and hepatitis C virus infection in chronic kidney failure]. Nephrol Ther 2015;11:507-20. [PMID: 26423779 DOI: 10.1016/j.nephro.2015.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
45 Toy M, Salomon JA, Jiang H, Gui H, Wang H, Wang J, Richardus JH, Xie Q. Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China: TOY ET AL. Hepatology 2014;60:46-55. [DOI: 10.1002/hep.26934] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
46 Huang E, Esrailian E, Spiegel BM. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis. Aliment Pharmacol Ther. 2007;26:1147-1161. [PMID: 17894657 DOI: 10.1111/j.1365-2036.2007.03464.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 3.5] [Reference Citation Analysis]
47 Toy M, Veldhuijzen IK, de Man RA, Richardus JH, Schalm SW. Potential impact of long-term nucleoside therapy on the mortality and morbidity of active chronic hepatitis B. Hepatology 2009;50:743-51. [DOI: 10.1002/hep.23061] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
48 Park JY, Heo J, Lee TJ, Yim HJ, Yeon JE, Lim YS, Seo MJ, Ahn SH, Lee MS. A novel estimation of the relative economic value in terms of different chronic hepatitis B treatment options. PLoS One 2013;8:e57900. [PMID: 23536775 DOI: 10.1371/journal.pone.0057900] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
49 Okada M, Enomoto M, Kawada N, Nguyen MH. Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis. Expert Rev Gastroenterol Hepatol. 2017;11:1095-1104. [PMID: 28752768 DOI: 10.1080/17474124.2017.1361822] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
50 Arnold DT, Bentham LM, Jacob RP, Lilford RJ, Girling AJ. Should patients with abnormal liver function tests in primary care be tested for chronic viral hepatitis: cost minimisation analysis based on a comprehensively tested cohort. BMC Fam Pract 2011;12:9. [PMID: 21371303 DOI: 10.1186/1471-2296-12-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
51 Woo G, Tomlinson G, Yim C, Lilly L, Therapondos G, Wong DK, Ungar WJ, Einarson TR, Sherman M, Heathcote JE, Krahn M. Health state utilities and quality of life in patients with hepatitis B. Can J Gastroenterol 2012;26:445-51. [PMID: 22803020 DOI: 10.1155/2012/736452] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
52 Lee KK, Wu DB, Chow PY, Lee VW, Li H. Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong. J Gastroenterol Hepatol. 2012;27:1167-1174. [PMID: 22141402 DOI: 10.1111/j.1440-1746.2011.07047.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
53 Veenstra DL, Sullivan SD, Clarke L, Iloeje UH, Tafesse E, Di Bisceglie A, Kowdley KV, Gish RG. Cost Effectiveness of Entecavir versus Lamivudine with Adefovir Salvage in HBeAg-Positive Chronic Hepatitis B: . PharmacoEconomics 2007;25:963-77. [DOI: 10.2165/00019053-200725110-00006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 1.8] [Reference Citation Analysis]